Whole-heart coronary magnetic resonance angiography with MS-325 (Gadofosveset)

Medical Science Monitor

Volumn 13, Issue 11, 2007, Pages

  Kelle, Sebastian ^a,b   Thouet, Thomas ^a   Tangcharoen, Tarinee ^a   Nassenstein, Kai ^c   Chiribiri, Amedeo ^d   Paetsch, Ingo ^a   Schnackenburg, Bernhard ^e   Barkhausen, Jörg ^c   Fleck, Eckart ^a   Nagel, Eike ^f  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF TURIN   (Italy)

^e PHILIPS HEALTHCARE   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiac magnetic resonance; Coronary artery imaging; Intravascular contrast agents

Indexed keywords

GADOFOSVESET;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NORMAL HUMAN; SIGNAL NOISE RATIO; STATISTICAL SIGNIFICANCE;

ADULT; CONTRAST MEDIA; CORONARY VESSELS; FEMALE; GADOLINIUM; HEART; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; ORGANOMETALLIC COMPOUNDS;

EID: 36148982243     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hendel RC et al: ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Computed Tomography and Cardiac Magnetic Resonance Imaging: A Report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol, 2006; 48(7): 1475-97
2. Kim WY et al: Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med, 2001; 345(26): 1863-69
3. Jahnke C et al: Coronary MR angiography with steady-state free precession: individually adapted breath-hold technique versus free-breathing technique. Radiology, 2004; 232(3): 669-76
4. Herborn CU et al: Coronary Arteries: Contrast-enhanced MR Imaging with SH L 643A - Experience in 12 Volunteers. Radiology, 2003; 229(1): 217-23
5. Stuber M et al: Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography. J Magn Reson Imaging, 1999; 10(5): 790-99
6. Paetsch I et al: Detection of coronary stenoses with contrast enhanced, three-dimensional free breathing coronary MR angiography using the gadolinium-based intravascular contrast agent gadocoletic acid (B-22956). J Cardiovasc Magn Reson, 2006; 8(3): 509-16
7. Nassenstein K et al: Magnetic Resonance Coronary Angiography with MS-325: in-vivo T1-measurements to improve image quality of navigator and breath-hold techniques. Eur Radiol, in press
8. Herborn CU et al: MR Coronary Angiography with SH L 643 A: Initial Experience in Patients with Coronary Artery Disease. Radiology, 2004; 233(2): 567-73
9. Lauffer RB et al: MS-325: albumin-targeted contrast agent for MR angiography. Radiology, 1998; 207(2): 529-38
10. Parmelee DJ et al: Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging. Invest Radiol, 1997; 32(12): 741-47
11. Bluemke DA et al: Carotid MR Angiography: Phase II Study of Safety and Efficacy for MS-325. Radiology, 2001; 219(1): 114-22
12. Grist TM et al: Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology, 1998; 207(2): 539-44
13. Weber OM, Martin AJ, Higgins CB: Whole-heart steady-state free precession coronary artery magnetic resonance angiography. Magn Reson Med, 2003; 50(6): 1223-28
14. Jahnke C et al: Rapid and complete coronary arterial tree visualization with magnetic resonance imaging: feasibility and diagnostic performance. Eur Heart J, 2005; 26(21): 2313-19
15. Prakken NH et al: 3D MR coronary angiography: optimization of the technique and preliminary results. Int J Cardiovasc Imaging, 2006; 22(3-4): 477-87
16. Look DC, Locker DR: Look-Locker - sequence. Rev Sci Instrum, 1970; 41(2): 250-51
17. Botnar RM et al: Improved coronary artery definition with T2-weighted, free-breathing, three-dimensional coronary MRA. Circulation, 1999; 99(24): 3139-48
18. Scanlon PJ et al: ACC/AHA guidelines for coronary angiography. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Coronary Angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol, 1999; 33(6): 1756-824
19. Nassenstein K et al: [MR coronary angiography with MS-325, a blood pool contrast agent: comparison of an inversion recovery steady-state free precession with an inversion recovery fast low angle shot sequence in volunteers]. Rofo, 2006; 178(5): 508-14
20. Etienne A et al: "Soap-Bubble" visualization and quantitative analysis of 3D coronary magnetic resonance angiograms. Magn Reson Med, 2002; 48(4): 658-66
21. Nikolaou K et al: High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology, 2006; 241(3): 861-72
22. Goyen M et al: MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology, 2005; 236(3): 825-33
23. Hartmann M et al: Initial imaging recommendations for Vasovist angiography. Eur Radiol, 2006; 16(Suppl.2): B15-23
24. Rapp JH et al: Aortoiliac Occlusive Disease in Patients with Known or Suspected Peripheral Vascular Disease: Safety and Efficacy of Gadofosveset-enhanced MR Angiography - Multicenter Comparative Phase III Study. Radiology, 2005; 236(1): 71-78
25. Lei T et al: 3D MRA visualization and artery-vein separation using blood-pool contrast agent MS-325. Acad Radiol, 2002; 9(Suppl.1): S127-33
26. Shamsi K, Yucel E, Chamberlin P: A Summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. Invest Radiol, 2006; 41(11): 822-30
27. Pedersen M: Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging, 2007; 25(5): 881-83
28. Li D et al: Three-dimensional MRI of coronary arteries using an intravascular contrast agent. Magn Reson Med, 1998; 39(6): 1014-18
29. Paetsch I et al: Improved three-dimensional free-breathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement. J Magn Reson Imaging, 2004; 20(2): 288-93
30. Klein C et al: Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease. J Magn Reson Imaging, 2003; 17(6): 656-62
31. Rohrer M et al: Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol, 2005; 40(11): 715-24
32. Sakuma H et al: Assessment of coronary arteries with total study time of less than 30 minutes by using whole-heart coronary MR angiography. Radiology, 2005; 237(1): 316-21
33. Ozgun M et al: [Whole-heart coronary MR angiography - initial results]. Rofo, 2006; 178(5): 500-7
34. Sakuma H et al: Detection of coronary artery stenosis with whole-heart coronary magnetic resonance angiography. J Am Coll Cardiol, 2006; 48(10): 1946-50
35. Nehrke K, Bornert P: Prospective correction of affine motion for arbitrary MR sequences on a clinical scanner. Magn Reson Med, 2005; 54(5): 1130-38
36. Huber ME et al: Performance of a new gadolinium-based intravascular contrast agent in free-breathing inversion-recovery 3D coronary MRA. Magn Reson Med, 2003; 49(1): 115-21
37. Stuber M, Weiss R: Coronary magnetic resonance angiography. J Magn Reson Imaging, 2007; 26(2): 219-34
38. Jahnke C et al: Prognostic Value of Cardiac Magnetic Resonance Stress Tests: Adenosine Stress Perfusion and Dobutamine Stress Wall Motion Imaging. Circulation, 2007; 115(13): 1769-76
39. Raff G et al: Diagnostic Accuracy of Noninvasive Coronary Angiography Using 64-Slice Spiral Computed Tomography. J Am Coll Cardiol, 2005; 46(3): 552-57
40. Jahnke C et al: A new approach for rapid assessment of the cardiac rest period for coronary MRA. J Cardiovasc Magn Reson, 2005; 7(2): 395-99
41. Jahnke C et al: Coronary MR Imaging: Breath-hold Capability and Patterns, Coronary Artery Rest Periods, and b-Blocker Use. Radiology, 2006; 239(1): 71-78
42. Stuber M et al: Preliminary report on in vivo coronary MRA at 3 Tesla in humans. Magn Reson Med, 2002; 48(3): 425-29
43. Sommer T et al: Coronary MR Angiography at 3.0 T versus That at 1.5 T: Initial Results in Patients Suspected of Having Coronary Artery Disease. Radiology, 2005; 234(3): 718-25